COVID-19 vaccine race: watch your step for cancer patients

Patients with cancer should benefit from COVID-19 vaccination. Some of the most advanced vaccine candidates are mRNAs encapsulated into lipid carriers, and small liposomes are expected to accumulate in tumour tissues through the enhanced and permeation retention effect. However, to what extent solid tumours could take up a significant part of the vaccine dose as well remains unknown. This calls for a careful evaluation of the efficacy of these promising mRNA COVID-19 vaccines administered as lipid carriers for patients with solid tumours, including a possible re-appraisal of the dosing for optimal protection of this specific and frail population.

• Publication year

  2020

• Venue

  British Journal of Cancer

• Publication date

  2020-12-07

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/s41416-020-01219-3PMID 33288844PMCID 7720437
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• COVID-19 and Cancer: a Comprehensive Review

  2020cited by this paper
• Recent Clinical Developments of Nanomediated Drug Delivery Systems of Taxanes for the Treatment of Cancer

  2020cited by this paper
• SARS-CoV-2 vaccines in development

  2020cited by this paper
• Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults

  2020cited by this paper
• Host Polymorphisms May Impact SARS-CoV-2 Infectivity

  2020cited by this paper
• Intratumoral Comparison of Nanoparticle Entrapped Docetaxel (CPC634) with Conventional Docetaxel in Patients with Solid Tumors

  2020cited by this paper
• Nanoscale delivery systems for microRNAs in cancer therapy

  2019cited by this paper
• A Comprehensive Review

  2017cited by this paper
• Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes.

  2015cited by this paper
• Biodistribution, Tumor Uptake and Efficacy of 5-FU-Loaded Liposomes: Why Size Matters

  2014cited by this paper
• Encapsulation, pharmacokinetics and tissue distribution of interferon α-2b liposomes after intramuscular injection to rats

  2011cited by this paper
• Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect.

  2009cited by this paper
• Why size matters.

  2006cited by this paper

• Insights in AAV-mediated antigen-specific immunity and a strategy for AAV vaccine dose reduction through AAV-extracellular vesicle association

  2024cites this paper
• Challenging Axillary Lymph Nodes on PET/CT in Cancer Patients Throughout COVID-19 Vaccination Era.

  2024cites this paper
• MicroRNAs Derived from Extracellular Vesicles: Keys to Understanding SARS-CoV-2 Vaccination Response in Cancer Patients?

  2023cites this paper
• Perception of the vaccination issue and vaccination against COVID-19 by palliative care users

  2023cites this paper
• Functionalized nanoparticles crossing the brain–blood barrier to target glioma cells

  2023cites this paper
• Anti-cancer effect of COVID-19 vaccines in mice models

  2023cites this paper
• SARS-CoV-2 vaccines from A to Z: A Review of the current challenges

  2023cites this paper
• Tumor antigen-loaded AAV vaccine drives protective immunity in a melanoma animal model

  2023cites this paper
• Enhancing drug penetration in solid tumors via nanomedicine: Evaluation models, strategies and perspectives

  2023cites this paper
• Adverse Events Reported by Patients With Cancer After Administration of a 2-Dose mRNA COVID-19 Vaccine.

  2022cites this paper
• Advances in vaccine delivery strategies to promote effective immunization

  2022cites this paper
• Acceptance, efficacy, and safety of COVID-19 vaccination in older patients with cancer

  2022cites this paper
• SARS-Cov-2 infection in cancer patients, susceptibility, outcome and care

  2022cites this paper
• Liposome as carrier therapy for Alzheimer’s disease

  2022cites this paper
• Cellular Immunity Is Critical for Assessing COVID-19 Vaccine Effectiveness in Immunocompromised Individuals

  2022cites this paper
• Liposomes are Poorly Absorbed via Lung Lymph After Inhaled Administration in Sheep

  2022cites this paper
• Coronavirus Disease 2019 Vaccination for Cancer Patients: Risk or Benefit?

  2022cites this paper
• Challenging Axillary Lymph-Nodes on F-18-FDG, F-18-Choline and Ga-68-DOTATOC PET/CT in Cancer Patients throughout Covid-19 Vaccination Era (preprint)

  2022cites this paper
• Cancer Patients Have Necessary Been COVID-19 Vaccinated

  2021cites this paper
• Development of neoantigens: from identification in cancer cells to application in cancer vaccines

  2021cites this paper
• COVID-19 and Malignancy: Exploration of the possible genetic and epigenetic interlinks and overview of the vaccination scenario

  2021cites this paper
• The Uro-oncology Patient and Vaccination Against SARS-CoV-2

  2021cites this paper
• COVID-19 Vaccines in Patients With Cancer-A Welcome Addition, but There Is Need for Optimization.

  2021cites this paper
• COVID-19 vaccination in a cancerous patient: A comment

  2021cites this paper
• Review of the Current Landscape of the Potential of Nanotechnology for Future Malaria Diagnosis, Treatment, and Vaccination Strategies

  2021cites this paper
• SARS-CoV-2 Vaccines in Patients With Multiple Myeloma

  2021cites this paper
• Challenges and Opportunities for COVID-19 Vaccines in Patients with Cancer

  2021cites this paper
• The Big Billion Indian COVID 19 Vaccine Challenge

  2021cites this paper
• Vaccination against SARS-COV‑2 in oncology

  2021cites this paper
• Recent updates on effectiveness of COVID-19 vaccines

  2021cites this paper
• Cancer or COVID-19? A Review of Recommendations for COVID-19 Vaccination in Cancer Patients

  2021cites this paper
• Reply to K. Takada et al.

  2021cites this paper
• Antiviral Potential of Naphthoquinones Derivatives Encapsulated within Liposomes

  2021cites this paper
• SARS-CoV-2, Cardiovascular Diseases, and Noncoding RNAs: A Connected Triad

  2021cites this paper
• MicroRNAs and Long Non-Coding RNAs as Potential Candidates to Target Specific Motifs of SARS-CoV-2

  2020cites this paper
• Adaptive immunity to SARS-CoV-2 in cancer patients: The CAPTURE study

  2020cites this paper